BESPONSA (inotuzumab Ozogamicin) Approved for Treatment of Adult Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia, Available for Order at Biologics, Inc.
August 22, 2017
August 22, 2017
CARY, N.C., Aug. 22 -- McKesson issued the following news release:
Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected by Pfizer, Inc. to be a specialty pharmacy provider for BESPONSA (inotuzumab ozogamicin), a promising new IV therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Approved by the U.S. Food and Drug Administration (FDA) on August 17, 20 . . .
Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected by Pfizer, Inc. to be a specialty pharmacy provider for BESPONSA (inotuzumab ozogamicin), a promising new IV therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Approved by the U.S. Food and Drug Administration (FDA) on August 17, 20 . . .